Fudan University
🇨🇳China
- Country
- 🇨🇳China
- Ownership
- Private
- Established
- 1905-01-01
- Employees
- 1K
- Market Cap
- -
- Website
- http://www.fudan.edu.cn
A Trial Exploring the Opportune Administration of Nab-paclitaxel in the First Line Treatment, Camrelizumab Combined With Nab-paclitaxel and Famitinib, of TNBC.
Phase 2
Recruiting
- Conditions
- Triple-Negative Breast Cancer
- Interventions
- First Posted Date
- 2023-01-04
- Last Posted Date
- 2023-02-28
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 46
- Registration Number
- NCT05670925
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center Shanghai, China, 200032, Shanghai, Shanghai, China
GEMOX Combined With Donafenib and Tislelizumab in Advanced Biliary Tract Carcinoma
Phase 2
Recruiting
- Conditions
- Biliary Tract Carcinoma
- Interventions
- Combination Product: Combination of Gemcitabine, Oxaliplatin, Donafenib and Tislelizumab
- First Posted Date
- 2022-12-30
- Last Posted Date
- 2024-08-16
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 93
- Registration Number
- NCT05668884
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
Feasibility in Identification of Breast Cancer Candidates for Elimination of Axillary Surgery
Not Applicable
Completed
- Conditions
- Breast Cancer
- Interventions
- Diagnostic Test: Ultrasound-guided core needle biopsy in breast
- First Posted Date
- 2022-12-23
- Last Posted Date
- 2022-12-23
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 191
- Registration Number
- NCT05663021
- Locations
- 🇨🇳
Zhi-Min Shao, Shanghai, Shanghai, China
Effect and Safety of Huaier Granules Combined With Targeted Drugs and Anti-PD-(L)1 Antibody Compared With Targeted Drugs Combined With Anti-PD-(L)1 Antibody in First Line Treatment of Unresectable Hepatocellular Carcinoma(uHCC)
Phase 4
Not yet recruiting
- Conditions
- Unresectable Hepatocellular Carcinoma
- Interventions
- Drug: Atezolizumab + BevacizumabDrug: Huaier granuleDrug: Camrelizumab+ApatinibDrug: Sintilimab+Bevacizumab
- First Posted Date
- 2022-12-21
- Last Posted Date
- 2023-12-18
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 600
- Registration Number
- NCT05660213
Neoadjuvant Envafolimab in Resectable and Locally Advanced MSI-H/dMMR Rectal Cancer
Not yet recruiting
- Conditions
- Locally Advanced Rectal CarcinomaMSI-High
- First Posted Date
- 2022-12-09
- Last Posted Date
- 2022-12-13
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 38
- Registration Number
- NCT05645094
Camrelizumab Combined With Bevacizumab and HAIC in Patients With Metastatic Liver Cancer Who Failed Standard Therapy
Phase 1
Not yet recruiting
- Conditions
- Metastatic Liver Cancer
- Interventions
- Drug: HAIC、Bevacizumab、Camrelizumab
- First Posted Date
- 2022-12-08
- Last Posted Date
- 2022-12-08
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 80
- Registration Number
- NCT05643417
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
Low Dose Decitabine in Combination With Tirelizumab Comparison of Tirelizumab in the First-line Treatment of Advanced Esophageal Squamous Cell Carcinoma
- First Posted Date
- 2022-12-06
- Last Posted Date
- 2022-12-06
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 60
- Registration Number
- NCT05638984
Evaluation of a Model for the Early Diagnosis of Colorectal Cancer by the Detection of 5-hydroxymethylcytosine (5-hmC) in Plasma Cell-free DNA to the Community Colorectal Cancer Screening Program
Recruiting
- Conditions
- Colorectal NeoplasmsColorectal Cancer
- First Posted Date
- 2022-12-06
- Last Posted Date
- 2022-12-06
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 10000
- Registration Number
- NCT05638243
- Locations
- 🇨🇳
Community Health Centers in Xuhui District, Shanghai, Shanghai, China
The Efficacy and Safety of Fruquintinib Plus FOLFIRI/FOLFOX as Second-line Treatment in Patients With RAS-mutant Metastatic Colorectal Cancer
Phase 2
Not yet recruiting
- Conditions
- Metastatic Colorectal Cancer
- Interventions
- First Posted Date
- 2022-12-02
- Last Posted Date
- 2022-12-02
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 68
- Registration Number
- NCT05634590
- Locations
- 🇨🇳
Department of Colorectal Surgery Fudan University Shanghai Caner Center, Shanghai, Shanghai, China
Predictive Value of ctDNA for NED Status in mCRC and Its Utility in Guiding Therapeutic Intervention
Not Applicable
Recruiting
- Conditions
- No Evidence of Disease StatusctDNA MonitoringMetastatic Colorectal Cancer
- Interventions
- Other: ctDNAOther: ctDNA and adjuvant therapy
- First Posted Date
- 2022-12-02
- Last Posted Date
- 2022-12-02
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 110
- Registration Number
- NCT05635630
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
© Copyright 2025. All Rights Reserved by MedPath